

Jung Hye Kwon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5250836/publications.pdf>

Version: 2024-02-01

104
papers

3,215
citations

218677

26
h-index

175258

52
g-index

108
all docs

108
docs citations

108
times ranked

4212
citing authors

#	ARTICLE	IF	CITATIONS
1	“The surprise questions” using variable time frames in hospitalized patients with advanced cancer. <i>Palliative and Supportive Care</i> , 2022, 20, 221-225.	1.0	7
2	Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01). <i>Korean Journal of Internal Medicine</i> , 2022, 37, 190-200.	1.7	2
3	Palliative Sedation in End-of-Life Patients in Eastern Asia: A Narrative Review. <i>Cancer Research and Treatment</i> , 2022, 54, 644-650.	3.0	3
4	Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study. <i>Cancers</i> , 2021, 13, 331.	3.7	4
5	Unmet needs related to the quality of life of advanced cancer patients in Korea: a qualitative study. <i>BMC Palliative Care</i> , 2021, 20, 58.	1.8	5
6	Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 10, 100126.	2.9	30
7	Development of a One-item Screening Question to Assess Spiritual Well-Being for Advanced Cancer Inpatients in Korea. <i>Journal of Pain and Symptom Management</i> , 2021, 62, 910-917.	1.2	3
8	Preparation and Practice of the Necessary Documents in Hospital for the “Act on Decision of Life-Sustaining Treatment for Patients at the End-of-Life”. <i>Cancer Research and Treatment</i> , 2021, 53, 926-934.	3.0	3
9	Life-Sustaining Treatment States in Korean Cancer Patients after Enforcement of Act on Decisions on Life-Sustaining Treatment for Patients at the End of Life. <i>Cancer Research and Treatment</i> , 2021, 53, 908-916.	3.0	14
10	Current Status and Cardinal Features of Patient Autonomy after Enactment of the Life-Sustaining Treatment Decisions Act in Korea. <i>Cancer Research and Treatment</i> , 2021, 53, 917-925.	3.0	6
11	The Situation of Life-Sustaining Treatment One Year after Enforcement of the Act on Decisions on Life-Sustaining Treatment for Patients at the End-of-Life in Korea: Data of National Agency for Management of Life-Sustaining Treatment. <i>Cancer Research and Treatment</i> , 2021, 53, 897-907.	3.0	11
12	Factors related to spiritual well-being in the last days of life in three East Asian countries: An international multicenter prospective cohort study. <i>Palliative Medicine</i> , 2021, 35, 1564-1577.	3.1	3
13	Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. <i>International Journal of Hematology</i> , 2021, 114, 355-362.	1.6	1
14	Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5272-5279.	7.0	26
15	Pilot study for the Psychometric Validation of the Sheffield Profile for Assessment and Referral to Care (SPARC) in Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2021, 53, 25-31.	3.0	5
16	Community Care for Cancer Patients in Rural Areas: An Integrated Regional Cancer Center and Public Health Center Partnership Model. <i>The Korean Journal of Hospice and Palliative Care</i> , 2021, 24, 226-234.	0.7	2
17	Awareness of Doctors’ Shared Decision-Making in Life-Sustaining Care Decisions. <i>The Korean Journal of Hospice and Palliative Care</i> , 2021, 24, 204-213.	0.7	1
18	Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy. <i>Oncologist</i> , 2020, 25, e502-e511.	3.7	32

#	ARTICLE	IF	CITATIONS
19	The Impacts of Prognostic Awareness on Mood and Quality of Life Among Patients With Advanced Cancer. <i>American Journal of Hospice and Palliative Medicine</i> , 2020, 37, 904-912.	1.4	18
20	The Attitudes of Physicians and the General Public toward Prognostic Disclosure of Different Serious Illnesses: a Korean Nationwide Study. <i>Journal of Korean Medical Science</i> , 2020, 35, e401.	2.5	0
21	The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores. <i>International Journal of Hematology</i> , 2019, 110, 438-446.	1.6	7
22	Attitudes of the General Public, Cancer Patients, Family Caregivers, and Physicians Toward Advance Care Planning: A Nationwide Survey Before the Enforcement of the Life-Sustaining Treatment Decision-Making Act. <i>Journal of Pain and Symptom Management</i> , 2019, 57, 774-782.	1.2	25
23	Sedation for terminally ill cancer patients. <i>Medicine (United States)</i> , 2019, 98, e14278.	1.0	12
24	Surrogate decision making of chemotherapy consent: do we really provide informed consent of chemotherapy for patients?. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 626-633.	1.7	1
25	Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2019, 51, 300-312.	3.0	48
26	Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 119-127.	3.0	23
27	Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 1249-1256.	3.0	5
28	Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 851-860.	3.0	14
29	Priorities of a "good death" according to cancer patients, their family caregivers, physicians, and the general population: a nationwide survey. <i>Supportive Care in Cancer</i> , 2018, 26, 3479-3488.	2.2	46
30	Attitudes toward early palliative care in cancer patients and caregivers: a Korean nationwide survey. <i>Cancer Medicine</i> , 2018, 7, 1784-1793.	2.8	22
31	Is spirituality related to survival in advanced cancer inpatients in Korea?. <i>Palliative and Supportive Care</i> , 2018, 16, 669-676.	1.0	10
32	Efficacy and safety of oxycodone/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e448-e454.	1.1	17
33	Factors Associated With Attrition in a Multicenter Longitudinal Observational Study of Patients With Advanced Cancer. <i>Journal of Pain and Symptom Management</i> , 2018, 55, 938-945.	1.2	23
34	Discordance between Physician and the General Public Perceptions of Prognostic Disclosure to Children with Serious Illness: a Korean Nationwide Study. <i>Journal of Korean Medical Science</i> , 2018, 33, e327.	2.5	7
35	Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis. <i>Journal of Cancer</i> , 2018, 9, 4279-4286.	2.5	38
36	Consensus guidelines for the definition of the end stage of disease and last days of life and criteria for medical judgment. <i>Journal of the Korean Medical Association</i> , 2018, 61, 509.	0.3	19

#	ARTICLE	IF	CITATIONS
37	Comparison of attitudes towards five end-of-life care interventions (active pain control, withdrawal) Tj ETQq1 1 0.784314 rgBT /Overl caregivers, physicians and the general Korean population. <i>BMI Open</i> , 2018, 8, e020519.	1.9	20
38	Spiritual Well-being Among Palliative Care Patients With Different Religious Affiliations: A Multicenter Korean Study. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 893-901.	1.2	16
39	Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. <i>British Journal of Cancer</i> , 2018, 118, 1169-1175.	6.4	25
40	Multicenter Retrospective Analysis of Clinical Characteristics, Treatment Patterns, and Outcomes in Very Elderly Patients with Diffuse Large B-Cell Lymphoma: The Korean Cancer Study Group LY16-01. <i>Cancer Research and Treatment</i> , 2018, 50, 590-598.	3.0	7
41	Off-Label Medication Use in the Inpatient Palliative Care Unit. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 46-54.	1.2	26
42	Utility of an immunoglobulin gene rearrangement assay based on multiplex PCR in detecting bone marrow involvement in B-cell non-Hodgkin lymphoma. <i>Blood Research</i> , 2017, 52, 141.	1.3	1
43	Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 92171-92182.	1.8	12
44	Attitudes of the General Population, Cancer Patients, their Family Caregivers, and Physicians toward Dying and Death: A Nationwide Survey. <i>Global Journal of Health Science</i> , 2017, 9, 201-11.	0.2	4
45	Minimal Clinically Important Difference in the Physical, Emotional, and Total Symptom Distress Scores of the Edmonton Symptom Assessment System. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 262-269.	1.2	115
46	Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. <i>Oncotarget</i> , 2016, 7, 72033-72043.	1.8	14
47	Adopting Advance Directives Reinforces Patient Participation in End-of-Life Care Discussion. <i>Cancer Research and Treatment</i> , 2016, 48, 753-758.	3.0	18
48	Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: A prospective, multicenter study. <i>Cancer</i> , 2015, 121, 3027-3035.	4.1	183
49	Frequency, Predictors, and Medical Record Documentation of Chemical Coping Among Advanced Cancer Patients. <i>Oncologist</i> , 2015, 20, 692-697.	3.7	79
50	Psychometric Validation of the Edmonton Symptom Assessment System in Chinese Patients. <i>Journal of Pain and Symptom Management</i> , 2015, 50, 712-717.e2.	1.2	26
51	Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 711-718.	2.3	11
52	Weekly rituximab consolidation following four cycles of Râ€œscp>CHOP</scp> induction chemotherapy in very elderly patients with diffuse large Bâ€œcell lymphoma: Consortium for improving survival of lymphoma study (<scp>CISL</scp>). <i>European Journal of Haematology</i> , 2015, 94, 504-510.	2.2	16
53	Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study. <i>International Journal of Hematology</i> , 2015, 102, 420-425.	1.6	3
54	A Pilot Study To Define Chemical Coping in Cancer Patients Using the Delphi Method. <i>Journal of Palliative Medicine</i> , 2015, 18, 703-706.	1.1	31

#	ARTICLE	IF	CITATIONS
55	The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma. <i>Cancer Research and Treatment</i> , 2015, 47, 458-464.	3.0	4
56	Chemical coping versus pseudoaddiction in patients with cancer pain. <i>Palliative and Supportive Care</i> , 2014, 12, 413-417.	1.0	39
57	A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma. <i>BMC Cancer</i> , 2014, 14, 795.	2.6	36
58	A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics. <i>Supportive Care in Cancer</i> , 2014, 22, 741-750.	2.2	10
59	Overcoming Barriers in Cancer Pain Management. <i>Journal of Clinical Oncology</i> , 2014, 32, 1727-1733.	1.6	265
60	Concepts and Definitions for "Actively Dying," "End of Life," "Terminally Ill," "Terminal Care," and "Transition of Care": A Systematic Review. <i>Journal of Pain and Symptom Management</i> , 2014, 47, 77-89.	1.2	233
61	Characteristics and Outcomes of Patients Admitted to the Acute Palliative Care Unit From the Emergency Center. <i>Journal of Pain and Symptom Management</i> , 2014, 47, 1028-1034.	1.2	29
62	Factors Associated With Survival After Opioid Rotation in Cancer Patients Presenting to an Outpatient Supportive Care Center. <i>Journal of Pain and Symptom Management</i> , 2014, 48, 92-98.	1.2	11
63	Predictors of high score patient-reported barriers to controlling cancer pain: a preliminary report. <i>Supportive Care in Cancer</i> , 2013, 21, 1175-1183.	2.2	21
64	Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1591-1597.	2.3	12
65	Validation of the Edmonton Symptom Assessment System in Korean Patients With Cancer. <i>Journal of Pain and Symptom Management</i> , 2013, 46, 947-956.	1.2	50
66	Characteristics of Advanced Cancer Patients With Cancer-Related Fatigue Enrolled in Clinical Trials and Patients Referred to Outpatient Palliative Care Clinics. <i>Journal of Pain and Symptom Management</i> , 2013, 45, 534-541.	1.2	13
67	Concepts and definitions for "supportive care," "best supportive care," "palliative care," and "hospice care" in the published literature, dictionaries, and textbooks. <i>Supportive Care in Cancer</i> , 2013, 21, 659-685.	2.2	249
68	Targeted Agent Use in Cancer Patients at the End of Life. <i>Journal of Pain and Symptom Management</i> , 2013, 46, 1-8.	1.2	59
69	Changes in Symptom Intensity Among Cancer Patients Receiving Outpatient Palliative Care. <i>Journal of Pain and Symptom Management</i> , 2013, 46, 652-660.	1.2	68
70	Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 845-852.	2.3	11
71	Consistency of symptom clusters among advanced cancer patients seen at an outpatient supportive care clinic in a tertiary cancer center. <i>Palliative and Supportive Care</i> , 2013, 11, 473-480.	1.0	31
72	Frequency, Outcome, and Predictors of Success Within 6 Weeks of an Opioid Rotation Among Outpatients with Cancer Receiving Strong Opioids. <i>Oncologist</i> , 2013, 18, 212-220.	3.7	51

#	ARTICLE	IF	CITATIONS
73	Predictors of Long-Term Opioid Treatment Among Patients Who Receive Chemoradiation for Head and Neck Cancer. <i>Oncologist</i> , 2013, 18, 768-774.	3.7	73
74	Clinical Characteristics of Cancer Patients Referred Early to Supportive and Palliative Care. <i>Journal of Palliative Medicine</i> , 2013, 16, 148-155.	1.1	36
75	Experience of Barriers to Pain Management in Patients Receiving Outpatient Palliative Care. <i>Journal of Palliative Medicine</i> , 2013, 16, 908-914.	1.1	25
76	Assessing Patient Care in Palliative Care Using the Healthcare Matrix. <i>Journal of Palliative Medicine</i> , 2013, 16, 987-992.	1.1	2
77	A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients. <i>Cancer Research and Treatment</i> , 2013, 45, 172-177.	3.0	4
78	Access to Palliative Care Among Patients Treated at a Comprehensive Cancer Center. <i>Oncologist</i> , 2012, 17, 1574-1580.	3.7	173
79	Primary Thyroid Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type: Clinical Manifestation and Outcome of a Rare Disease – Consortium for Improving Survival of Lymphoma Study. <i>Acta Haematologica</i> , 2012, 127, 100-104.	1.4	16
80	Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. <i>Investigational New Drugs</i> , 2012, 30, 1984-1990.	2.6	59
81	Waldeyer’s ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL). <i>International Journal of Hematology</i> , 2012, 96, 631-637.	1.6	5
82	Clinical features and outcomes of Hodgkin’s lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL). <i>Annals of Hematology</i> , 2012, 91, 223-233.	1.8	11
83	Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL). <i>BMC Cancer</i> , 2011, 11, 321.	2.6	107
84	A phase II study of mitomycin-C and S-1 as third-line chemotherapy in patients with advanced colorectal cancer. <i>Oncology Letters</i> , 2011, 2, 1253-1256.	1.8	2
85	Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. <i>Blood</i> , 2011, 117, 1958-1965.	1.4	121
86	Calcified Carcinoma of the Gallbladder with Calcified Nodal Metastasis Presenting as a Porcelain Gallbladder: A Case Report. <i>Cancer Research and Treatment</i> , 2011, 43, 71-74.	3.0	7
87	Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 889-897.	2.3	5
88	Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study. <i>International Journal of Hematology</i> , 2010, 92, 510-517.	1.6	13
89	Stage IV marginal zone B-cell lymphoma – prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. <i>Cancer Science</i> , 2010, 101, 2443-2447.	3.9	8
90	A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 70, 71-76.	2.0	16

#	ARTICLE	IF	CITATIONS
91	Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry. <i>Acta Haematologica</i> , 2009, 122, 200-210.	1.4	28
92	Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases. <i>American Journal of Hematology</i> , 2009, 84, 826-829.	4.1	10
93	Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 509-516.	2.3	10
94	Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 877-883.	2.3	18
95	Systemic chemotherapy after cranial irradiation in patients with brain metastases from non-small cell lung cancer: A retrospective study. <i>Lung Cancer</i> , 2009, 63, 405-409.	2.0	10
96	Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 64, 121-123.	2.0	6
97	Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: A prospective, multicenter trial. <i>Lung Cancer</i> , 2009, 66, 338-343.	2.0	16
98	Bortezomib and the Increased Incidence of Herpes Zoster in Patients with Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 237-240.	1.4	59
99	A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2006, 54, 57-62.	2.0	17
100	Docetaxel + 5-Fluorouracil + Cisplatin 3-day Combination Chemotherapy as a First-line Treatment in Patients with Unresectable Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005, 35, 380-385.	1.3	15
101	Paclitaxel/Platinum-based Perioperative Chemotherapy and Surgery in Stage IIIA Non-small Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005, 35, 6-12.	1.3	6
102	Single-agent Capecitabine in Patients with Metastatic Colorectal Cancer Refractory to 5-Fluorouracil/Leucovorin Chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2004, 34, 400-404.	1.3	23
103	Induction of cytotoxic T lymphocytes by dendritic cells pulsed with murine leukemic cell RNA. <i>American Journal of Hematology</i> , 2004, 75, 121-127.	4.1	9
104	Erythropoietin Response Is Inadequate in Cancer Patients Receiving Chemotherapy. <i>International Journal of Hematology</i> , 2001, 74, 416-420.	1.6	6